POLYMORPHISM OF MDR1 GENE – RESISTANCE MARKERS TO CHEMOTHERAPY AT ONCOLOGICAL DISEASES

Purpose: Determination of a personal genotype of drug stability of cancer patients according to polymorphic marker 3435T MDR1 gene to predict individual chemotherapy regime. Methods: During the implementation of studies, DNA samples obtained from peripheral blood leukocytes of patients suffering from breast cancer (BC) (80 patients) and NHL (75 patients) were used. Results: Identifying genetic features in patients in the polymorphic marker C3435T gene MDR1 allows you to predict the nature of the pharmacological response, which makes it possible to improve the efficiency and safety of drug use - dose. The frequency of occurrence of genotypes among healthy donors and oncological patients with diagnosis of breast cancer and non-Hodgkin's lymphoma was carried out. Conclusions: It has been shown that the frequency of occurrence of homozygous TT genotype in breast cancer and Non-Hodgkin's lymphoma is higher than the occurrence of CC and CT genotypes.